Predicting the Efficacy of Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Using an AI Platform Based on Multi-parametric MRI
Launched by SIXTH AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Aug 29, 2022
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well a new artificial intelligence (AI) tool can predict how effective a treatment called neoadjuvant therapy will be for patients with locally advanced rectal cancer. Neoadjuvant therapy usually includes chemotherapy and radiation before surgery to help shrink the cancer. The researchers will use advanced MRI scans to gather detailed images and data, which will help them see if this AI model can accurately assess how well the treatment is working. By doing so, they aim to improve how doctors make treatment decisions for their patients.
To be eligible for the trial, participants need to be between 18 and 70 years old, have a confirmed diagnosis of rectal cancer, and have undergone specific MRI exams and treatments. They also need to be able to give informed consent, meaning they understand what the trial involves. Participants can expect to have their MRI images analyzed using this new technology, which may help provide better predictions about their treatment response. The study is currently recruiting participants, and it's important to note that some individuals may not qualify based on certain medical conditions or prior treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical suspicion or colonoscopic pathology of rectal cancer
- • Age over 18 years
- • Informed consent and signed informed consent form
- Exclusion Criteria:
- • Poor magnetic resonance image quality, such as severe artifacts
- • Previous treatment for rectal cancer
- • History or combination of other malignant tumours
- • Not Locally Advanced Rectal Cancer (LARC)
- • Not received neoadjuvant therapy or not completed neoadjuvant therapy
- • No surgery
- • Time interval between MRI and surgery was more than 2 weeks
- • Patients were lost to follow-up and voluntarily withdrew from the study due to adverse reactions or other reasons
About Sixth Affiliated Hospital, Sun Yat Sen University
The Sixth Affiliated Hospital of Sun Yat-sen University is a leading medical institution in China, dedicated to advancing healthcare through innovative clinical research and patient-centered care. As a prominent academic hospital, it integrates clinical practice with research excellence, fostering collaboration among multidisciplinary teams to enhance medical knowledge and improve patient outcomes. The hospital is committed to conducting rigorous clinical trials that adhere to the highest ethical standards, aiming to contribute to the global scientific community and support the development of new therapies and interventions. With a focus on translational medicine, the Sixth Affiliated Hospital actively engages in pioneering studies that address critical health challenges and promote evidence-based practices in diverse medical fields.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Zhuhai, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials